Shares of Epizyme (NASDAQ: EPZM) rallied sharply higher following data showing its lead drug candidate, tazemetost, delivered solid response rates in follicular lymphoma. Shares finished trading today up 17.4%.
Tazemetostat won fast-track status this spring for use in relapsed or refractory follicular lymphoma, either with wild-type EZH2 or with EZH2 activating mutations.
IMAGE SOURCE: GETTY IMAGES.